Clinical Report: Integrating Sleep Quality Indicators with VR Motion Analysis
Overview
This study demonstrates that combining virtual reality (VR) motion analysis with sleep quality indicators significantly enhances the early identification of mild cognitive impairment (MCI). The integration of these modalities provides a robust predictive tool for distinguishing MCI from healthy controls.
Background
Alzheimer's disease (AD) is a growing global health concern, with early identification of at-risk individuals being crucial for timely intervention. Sleep disorders are prevalent and have been linked to cognitive decline, making the assessment of sleep quality vital in the context of MCI. Traditional cognitive assessments may overlook subtle deficits, highlighting the need for innovative approaches that incorporate objective measures.
Data Highlights
Measure
MCI (n=38)
Healthy Controls (n=28)
PSQI Score
Higher
Lower
Task Completion Time
Longer
Shorter
Accuracy
Lower
Higher
AUC for Predictive Accuracy
0.863
-
Sensitivity
86.84%
-
Specificity
71.43%
-
Key Findings
Patients with MCI exhibited significantly poorer sleep quality compared to healthy controls, as measured by the Pittsburgh Sleep Quality Index (PSQI).
MCI patients required more time and achieved lower accuracy in VR tasks than healthy controls.
Strong correlations were found between VR performance metrics and cognitive test scores (MoCA and MMSE).
Integrating VR-derived digital markers with sleep quality metrics improved predictive accuracy for MCI detection (AUC = 0.863).
This multimodal approach is noninvasive and enhances clinical decision-making for early AD identification.
Clinical Implications
The findings suggest that clinicians should consider integrating VR-based assessments with sleep quality evaluations to enhance early detection of cognitive impairment. This approach may facilitate timely interventions and personalized treatment strategies for at-risk individuals.
Conclusion
The integration of VR motion analysis with sleep quality indicators represents a promising advancement in the early identification of mild cognitive impairment, potentially improving clinical outcomes for patients at risk of Alzheimer's disease.
